[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350563-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-350563-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","bioinformatics-screening-identifies-usp9x-as-a-pathogenic-gene-underlying-thyroid-and-breast-cancer-comorbidity","Bioinformatics screening identifies USP9X as a pathogenic gene underlying thyroid and breast cancer comorbidity","","The co-occurrence of thyroid cancer and breast cancer has drawn increasing attention. This study aimed to uncover potential molecular mechanisms underlying their comorbidity by identifying differentially expressed genes from TCGA and screening common driver genes. Bioinformatics analyses confirmed shared driver genes, with immunohistochemistry validating USP9X expression in co-occurring tumors. Functional assays showed that USP9X interference suppressed migration, invasion, and colony formation, while protein-interaction network results implicated USP9X-linked pathways as contributors. Findings suggest USP9X overexpression may represent a therapeutic target.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/bioinformatics-screening-identifies-usp9x-as-a-pathogenic-gene-underlying-thyroid-and-breast-cancer-comorbidity/350563/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/bioinformatics-screening-identifies-usp9x-as-a-pathogenic-gene-underlying-thyroid-and-breast-cancer-comorbidity/350563.png","ImageObject",300,407,{"name":42,"@type":43},"Bulrr","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What is the main goal of this study on thyroid and breast cancer comorbidity?","Question",{"text":62,"@type":63},"To explore the potential molecular mechanisms responsible for the comorbidity by identifying shared driver genes and common pathogenic pathways between thyroid cancer and breast cancer.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How was USP9X assessed in thyroid and breast cancer samples?",{"text":67,"@type":63},"Immunohistochemical staining was used to verify USP9X expression in double primary cancers with co-occurrence of thyroid cancer and breast cancer.",{"name":69,"@type":60,"acceptedAnswer":70},"What effects does USP9X interference have on cancer cell behaviors?",{"text":71,"@type":63},"Interfering with USP9X expression inhibited colony formation, migration, and invasion abilities of thyroid and breast cancer cells in vitro.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},350563,1790189334,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Journal of Molecular Histology (2026) 57:227  \n[https://doi.org/10.1007/s10735-026-10882-4](https://doi.org/10.1007/s10735-026-10882-4)  \nORIGINAL PAPER  \nBioinformatics screening identifies USP9X as a pathogenic gene underlying thyroid and breast cancer comorbidity  \nSiping Xiong1 · Yimin Guo1 · Miao Zhang4 · Shijun Sun3 · Yanghui Wei2 · Chao Zeng1  \nReceived: 12 May 2026 / Accepted: 27 June 2026 / Published online: 8 July 2026 © The Author(s) 2026  \nAbstract  \nThe co-occurrence of thyroid cancer (TC) and breast cancer (BC) has attracted much attention in recent years. The aim of the study was to explore the potential molecular mechanisms in the comorbidity of TC and BC. We identified the differentially expressed genes (DEGs) for TC and BC using the TCGA database and screened the common driver genes for the comorbidity of TC and BC. Immunohistochemical staining was performed to verify the expression of the common gene (USP9X) in double primary cancers (co-occurrence ofTC and BC) . Migration, invasion and colony formation assays were used to evaluate the role of USP9X in TC and BC cells in vitro. In the present study, we confirmed 8 driver genes shared by TC and BC through bioinformatics analysis. In samples with co-occurring TC and BC, USP9X immunoreactivity was detected in 100%(14/14) TC and 100%(14/14) BC samples. Interfering with USP9X expression could inhibit the colony formation, migration and invasion abilities of TC and BC cells. Protein-protein interaction network analysis revealed USP9X/MCL-1 and USP9X/NUAK1 might be molecular pathways involved in the comorbidity of TC and BC. Our findings suggest that USP9X overexpression is a molecular event involved in the comorbidity of TC and BC and it could be a promising therapeutic target.  \nKeywords USP9X · Comorbidity · Thyroid cancer · Breast cancer  \nSiping Xiong and Yimin Guo contributed equally to this work.  \n Shijun Sun [sunsj999@163.com](sunsj999@163.com)  \n􀀍 Yanghui Wei [weiyh23@sysu.edu.cn](weiyh23@sysu.edu.cn)  \n􀀍 Chao Zeng [zengch35@mail.sysu.edu.cn](zengch35@mail.sysu.edu.cn)  \n1 Department of Pathology, The Eighth Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518033, Guangdong, China  \n2 Department of Thyroid Surgery, The Eighth Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518033, Guangdong, China  \n3 Department of Pathology, Zhongshan City People’s Hospital, Zhongshan 528403, Guangdong, China  \n4 Department of Pathology, Jiangmen Xinhui District Maternal and Child Health Care Hospital, Jiangmen 529100, Guangdong, China  \nAbbreviations  \nBC breast cancer  \nSIR standardized incidence ratio  \nGO gene ontology  \nDEGs differentially expressed genes CC cellular component  \nSMG significantly mutated genes ER especially estrogen  \nTSH thyroid-stimulating hormone TC thyroid cancer  \nCOMP cartilage oligomeric matrix protein KEGG kyoto encyclopedia of genes and genomes BP biological process  \nMF molecular function  \nBMR background mutation Rate EGFR epidermal growth factor receptor COX-2 cyclooxygenase-2  \nIntroduction  \nBreast cancer (BC), the most common malignancy among women worldwide, accounted for 11.6% of newly diagnosed cancer cases in 2022 (Bray et al. 2024) . The incidence of thyroid cancer (TC) is also on the rise, currently ranking as one of the most common cancers affecting females (Siegelet al. 2025). With BC and TC being two malignancies with high incidence among women, the co-occurrence of these cancers in the same patient has attracted significant attention in recent years. Tanaka et al. conducted a retrospective cohort study of 2786 patients who were newly diagnosed with BC, revealing that this population had a significantly elevated risk of developing TC (Tanaka et al. 2001) . Piek et al. also reported that both the standardized incidence ratios of TC after BC diagnosis (1.86) and ofBC after TC diagnosis (1.46) were higher than the predicted rates in the general population (Piek et al. 2022) . The risk of BC in TC survivors increas","cbCaijH2PxCjzKot","https://ap.wps.com/l/cbCaijH2PxCjzKot","pdf",6278796,17,"English","# Abstract\n## Introduction","[{\"question\":\"What is the main goal of this study on thyroid and breast cancer comorbidity?\",\"answer\":\"To explore the potential molecular mechanisms responsible for the comorbidity by identifying shared driver genes and common pathogenic pathways between thyroid cancer and breast cancer.\"},{\"question\":\"How was USP9X assessed in thyroid and breast cancer samples?\",\"answer\":\"Immunohistochemical staining was used to verify USP9X expression in double primary cancers with co-occurrence of thyroid cancer and breast cancer.\"},{\"question\":\"What effects does USP9X interference have on cancer cell behaviors?\",\"answer\":\"Interfering with USP9X expression inhibited colony formation, migration, and invasion abilities of thyroid and breast cancer cells in vitro.\"}]","Bioinformatics screening identifies USP9X as a pathogenic gene underlying thyroid and breast cancer comorbidity | PDF",1790089639,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de271e0e8cd94d605d19c2c8fdbb6ba6.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b798071e8f86c51eb3cf7fccbfdd886.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e427b3c2051bd09b76f6a2bd7e6bff1.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/020df5fb8ed0a0d838a3cf63cc9869e3.webp",980,1301]